r/SpectralAI

Following the broad response and discussion around my previous post, I thought it was worth revisiting one part of the DeepView thesis that may be especially useful for those newer to the Spectral AI community: the potential health economics. This has been discussed before, but I think it’s important when considering commercialization and adoption.

Spectral estimates ~$24,000 in potential savings per burn stay, while an earlier SEC filing estimated ~$63,100 per DFU stay. These are company estimates, not yet proven real-world savings — which is exactly why the BARDA-supported health-economic and outcome research is interesting.

I also think this needs to be viewed in the context of management’s longer-term strategy. DeepView isn’t intended to remain simply a burn device. The broader vision is a wound-diagnostics medtech platform, with burn as the first FDA-authorized indication and potential expansion into DFU and other wounds. If successful, the opportunity becomes much larger than the burn-center market alone.

The economics could also extend beyond treatment itself. Better Day-One wound assessment could improve triage — determining who needs routine care, transfer to a burn/trauma center, or earlier intervention — potentially reducing unnecessary transfers, procedures, hospital stays and complications.

Longer term, if real-world evidence confirms meaningful reductions in total cost of care across wound indications, the incentive could extend beyond hospitals. Insurers and other payers could potentially encourage or incentivize objective wound assessment to reduce downstream healthcare costs.

That’s speculative today. But BARDA is helping fund the research that could determine whether this broader economic thesis holds up in the real world.

Sources:
Current SEC filing / BARDA (March 31, 2026):
https://www.sec.gov/Archives/edgar/data/1833498/000121390026055226/ea0289162-10q_spectral.htm

Earlier SEC filing / DFU estimate (December 31, 2023):
https://www.sec.gov/Archives/edgar/data/1833498/000121390024027863/ea0202419-10k_spectral.htm

Post your thoughts here about $MDAI when you do not think it constitutes a full post!

https://spectralmd.gcs-web.com/node/9841/pdf

Some people hate dilution, but in the case of $MDAI, selling these shares brings in cash, which is needed to develop new uses for the platform and fund commercialization. While more shares will be out there, hopefully, excellent execution by Vince and the team will create a much bigger pie for everyone to enjoy, while we also fund a device that will improve burn care. What if you need it yourself someday, or your family?

In fact, you can virtue signal to everyone that you are funding a critical medical device that will help America's readiness for mass casualty events!

-ChatGPT

https://spectralmd.gcs-web.com/news-events/events

Saw this quietly filed a couple weeks ago: https://www.sec.gov/Archives/edgar/data/2042176/000121390026081386/ea0299132-rw_spectral.htm

The interesting thing is it still was a subsidiary of Spectral AI and registered at the same Dallas office from what I could cross reference from publicly available data. So was technically an overhang on the books for Spectral AI until recently. I haven't seen if the Texas entity was formally dissolved yet (Spectral IP, Inc.).

I'm speculating this should be good for MDAI? Spangenberg seems to have moved on, we know he already sold most of his shares, and Spectral appears to now be cleaning up their books. For me personally, when I first discovered Spectral AI others I knew really didn't like the investment because of Spangenberg's involvement and this spinoff. It seemed to raise the eyebrow of suspicion. Curious if this will change how the street views MDAI as a serious investment. It certainly helps with future M&A to have this cleaned up.

Anyone have any thoughts on this? I'm curious if it will come up on earnings tomorrow.

* This was the spinoff that was long talked about where current MDAI shareholders would get shares in the Spectral IP IPO as a one time dividend. This now seems to be officially dead for the forseeable future.

* I believe Reed Smith LLP is still counsel for MDAI

Post your thoughts here about $MDAI when you do not think it constitutes a full post!

Another small but notable marketing event for DeepView. BARDA made a post a couple weeks back on LinkedIn, that MDAI highlighted too, about the success of DeepView as relates to BARDA's purpose in helping bring novel medical countermeasures to market.

https://www.medicalcountermeasures.gov/barda/fdaapprovals

Product 113 from the link above.

Hopefully this is one of many that is slowly getting the word out as they accelerate commercialization.